ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company which engaged in improving patients' lives by overcoming resistance in cancer. Co. develops therapies targeting hormone-dependent cancers, precision oncology, and key tumor dependencies. Co.'s clinical-stage products include ORIC-114, a brain-penetrant inhibitor targeting EGFR and HER2 for genetically defined cancers; ORIC-944, an allosteric inhibitor of PRC2 for prostate cancer; and ORIC-533, an orally bioavailable inhibitor of CD73, which plays a role in resistance to chemotherapy and immunotherapy. The ORIC YTD return is shown above.
The YTD Return on the ORIC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ORIC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ORIC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|